Metformin Shown to Prevent Long COVID Across Risk Groups in Multiple Randomized Trials

Why It Matters

Preventing Long COVID could curb chronic disability and healthcare costs, offering a low‑cost, widely available tool for pandemic mitigation.

Key Takeaways

• Metformin cuts Long COVID risk across risk groups
• One case prevented per 50 treated patients
• Fourteen‑day course safe, no hypoglycemia reported
• Effective alongside antivirals such as Paxlovid
• Pediatric efficacy remains unknown

Pulse Analysis

Long COVID has emerged as a costly, debilitating sequela affecting millions of post‑acute SARS‑CoV‑2 patients, prompting urgent searches for preventive therapies. Metformin, a first‑line oral antihyperglycemic agent, has attracted attention due to its anti‑inflammatory and antiviral properties mediated through AMPK activation and reduced viral replication. Recent analyses suggest that initiating metformin at the time of infection can blunt the inflammatory cascade that underlies persistent symptoms. By repurposing a drug with a well‑established safety record, researchers aim to offer a scalable, low‑cost solution that can be deployed globally without extensive new manufacturing pipelines.

The evidence now spans four high‑quality studies, including two large, placebo‑controlled randomized trials covering low, standard, and high‑risk adult cohorts. Across these trials, a 14‑day metformin regimen reduced the incidence of Long COVID, with a number‑needed‑to‑treat of roughly 50 acute cases to prevent one chronic case. Importantly, metformin demonstrated additive benefits when co‑administered with FDA‑approved antivirals such as nirmatrelvir‑ritonavir, molnupiravir, or remdesivir, and it did not precipitate hypoglycemia or serious adverse events in the studied populations.

While the data are compelling, gaps remain. Pediatric populations have not been evaluated, and the drug’s therapeutic role for patients already experiencing Long COVID is still unclear. Ongoing trials will clarify optimal dosing, timing, and potential interactions with emerging COVID‑19 therapeutics. If regulatory agencies endorse metformin for this indication, clinicians could incorporate it into early‑treatment protocols, potentially reducing long‑term healthcare utilization and improving quality of life for millions. The findings underscore the value of drug repurposing in pandemic response and may reshape post‑COVID care pathways.